甲状腺乳头状癌中M2型丙酮酸激酶的表达及其与BRAF基因突变的关系  

Expression of pyruvate kinase isoform M2 and its relationship with BRAF mutation in papillary thyroid carcinoma

作　　者：张薇[1] 王翠芳[2] 关海霞[3] 

机构地区：[1]中国医科大学附属盛京医院内分泌科,辽宁沈阳110004 [2]沈阳医学院奉天医院病理科,辽宁沈阳110024 [3]中国医科大学附属第一医院内分泌科,辽宁沈阳110001

出　　处：《肿瘤》2013年第4期350-354,共5页Tumor

基　　金：国家自然科学基金资助项目(编号:30801120)

摘　　要：目的:检测甲状腺乳头状癌(papillary thyroid carcinoma,PTC)中M2型丙酮酸激酶(M2 isoform of pyruvate kinase,PKM2)的表达,并探讨其与临床病理特征及BRAF(B-type Rafkinase)基因突变之间的关系。方法:采用免疫组织化学法分别对82例PTC组织、40例正常甲状腺组织及20例结节性甲状腺肿组织中PKM2的表达情况进行检测;应用PCR法扩增获得BRAF基因,并用直接测序的方法对BRAF基因突变的情况进行检测。结果:免疫组织化学结果提示,82例PTC组织中有75例(91.5%)具有不同程度PKM2蛋白的表达,在正常甲状腺组织及结节性甲状腺肿组织中PKM2蛋白表达均为阴性。PKM2的表达与T临床分期及淋巴结转移相关(P<0.05)。携带BRAF基因突变的PTC组织中PKM2表达强度更强,BRAF基因突变组为100.0%(46/46),而BRAF基因未突变组为86.1%(31/36)(P<0.05)。结论:PKM2在PTC中表达增加,其表达与PTC的恶性程度及BRAF基因是否突变密切相关。Objective： To explore the relationship between PKM2 （M2 isoform of pyruvate kinase） expression and the clinicopathological features and BRAF （B-type Raf kinase） gene mutation in human PTC （papillary thyroid carcinoma）. Methods： The expressions of PKM2 protein in 82 human PTC tissue samples, 40 human normal thyroid tissue samples and 20 human nodular goiter tissue samples were detected by immunohistochemistry. The BRAF gene mutation status in PTC tissues was examined using PCR （polymerase chain reaction） amplication and direct sequencing. Results： The expression level of PKM2 protein varied in 91.5% （75 of 82） of PTC tissues. Otherwise, there was no expression of PKM2 in normal thyroid tissues and nodular goiter tissues. The expression of PKM2 was associated with T staging and lymphatic metastasis （P 〈 0.05）. The positive rates of PKM2 expression in 46 PTC tissue samples carrying a BRAF mutation and 36 PTC tissue samples carrying wild type BRAF were 100.0% （46/46） and 86.1% （31/36）, respectively （P 〈 0.05）. Conclusion： This study demonstrated that the over-expression of PKM2 is associated with the aggressiveness of PTC and BRAF gene mutation status.

关 键 词：甲状腺肿瘤 丙酮酸激酶 免疫组织化学 核苷酸序列分析 BRAF基因 

分 类 号：R736.1[医药卫生—肿瘤]